Acquisition Expected to Close Today
Deal Valued at $9.7 Billion

Thousand Oaks, CA (Press Release) - Amgen (NASDAQ:AMGN) today announced that it has suc­cess­fully com­pleted its pre­vi­ously announced tender offer to purchase all outstanding shares of common stock of Onyx Pharma­ceu­ticals, Inc. (NASDAQ:ONXX) for $125 per share in cash. As announced on Aug. 25, the pur­chase price is $9.7 billion net of esti­mated Onyx cash. The tender offer expired at 12:00 midnight New York City time on Oct. 1, 2013. Amgen ex­pec­ts to com­plete the acquisition of Onyx later today through a merger under Section 251(h) of the General Corpo­ra­tion …

Findings provide insights for new, targeted cancer ther­a­pies in clin­i­cal trials

Scottsdale, AZ (Press Release) - Researchers have discovered why multiple myeloma, a dif­fi­cult to cure cancer of the bone marrow, frequently recurs after an initially effective treat­ment that can keep the disease at bay for up to several years.

Working in col­lab­o­ration with colleagues at Princess Margaret Cancer Centre in Toronto, researchers from Mayo Clinic in Arizonaand the Translational Genomics Research Institute (TGen) in Phoenix were part of the team that conducted the study published in the Sept. 9 issue of …

- Orphan desig­na­tion con­firmed for PAT-SM6 clin­i­cal prod­uct
- Provides 10 years market exclusivity in Europe post approval 
- PAT-SM6 is active in multiple myeloma patients with end stage disease who are resistant to other marketed ther­a­pies

Melbourne, Australia (Press Release) - Patrys Limited (ASX: PAB), a clin­i­cal stage bio­technology com­pany is pleased to announce that lead anti-cancer prod­uct PAT-SM6 has been granted orphan drug desig­na­tion by the European Medicines Agency (EMA) for multiple myeloma.

Orphan drug status is awarded to drugs that offer poten­tial thera­peutic value in the treat­ment of rare dis­eases …

Birmingham, AL (Press Release) - The University of Alabama at Birmingham Division of Hematology & Oncology and Bone Marrow Transplant Program have estab­lish­ed the only multidisciplinary myeloma clinic in Alabama.

Myeloma is a blood cancer that develops in the bone marrow, the soft, spongy center of most bones. Many blood cells are produced in the bone marrow, and myeloma affects plasma cells, a type of bone marrow cell that helps fight in­fec­tion. In multiple myeloma, normal plasma cells transform into malignant myeloma cells. The affected marrow space weakens, resulting in destruction of …

• After initial data read-out in Part 1, study may possibly be expanded and continued in Part 2 for use as a potential registration study
• Patient recruitment expected to start soon

Copenhagen (Press Release) - Genmab A/S (OMX: GEN) announced today that its partner, Janssen Bio­tech, Inc. ("Janssen") will start a new Phase II study of dara­tu­mu­mab in multiple myeloma.  The Phase II study is designed in 2 parts in multiple myeloma patients who have received at least three dif­fer­en­t lines of ther­apy in­­clud­ing both a pro­te­a­some inhibitor and an immuno­modu­la­tory agent (IMiD) or who are double refractory to a pro­te­a­some inhibitor and an IMiD.  This is the same indi­ca­tion for which dara­tu­mu­mab was granted Break­through Therapy Desig­na­tion from the …

Toronto (Press Release) – Clinical researchers at Princess Margaret Cancer Centre have discovered why multiple myeloma, an incurable cancer of the bone marrow, persistently escapes cure by an initially effective treat­ment that can keep the disease at bay for up to several years.

The reason, explains research published online today in Cancer Cell, is intrinsic resistance found in im­ma­ture pro­gen­i­tor cells that are the root cause of the disease – and relapse – says principal investigator Dr. Rodger Tiedemann, a hematologist specializing in multiple myeloma and lym­phoma at the Princess Mar­garet, University Health …

San Antonio (Press Release) - America Stem Cell, Inc. (ASC) announced today it has received clearance from FDA for its Phase I/IIa nationwide multi-center dual-umbilical cord trans­plan­ta­tion study eval­u­ating ASC-101 in patients with hema­to­logic malig­nan­cies and myelo­dys­plastic syn­drome.

ASC-101 is cur­rently undergoing evaluation in a single-center study at The University of Texas MD Anderson Cancer. To date, 12 patients have been enrolled in the study with 9 patients evaluable. On the basis of data obtained in the single-center study, FDA has given approval to proceed with a multi-center trial.

"Enhancing umbilical cord stem cell …